Skip to search formSkip to main contentSkip to account menu

RAF265

Known as: B-Raf/VEGFR-2 Inhibitor RAF265, RAF-265 
An orally bioavailable small molecule with potential antineoplastic activity. CHIR-265 binds and inhibits Raf kinases, which may result in a… 
National Institutes of Health

Related topics

Related topics

4 relations

Narrower (1)

CHIR-265

Broader (2)

ImidazolesPyridines
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Імуногістохімічна характеристика експресії VEGF-A, VEGFR-1, VEGFR-2 і CD34 при прогресуванні колоректальної аденокарциноми
Aim – to study VEGF-A, VEGFR-1, VEGFR-2 and CD34 immunohistochemical expression on the I, II, III, IV stages (pTNM) of colorectal… 
2015
2015
Discovery of RAF 265 : A Potent mut-B-RAF Inhibitor for the Treatment of Metastatic Melanoma
Abrogation of errant signaling along the MAPK pathway through the inhibition of B-RAF kinase is a validated approach for the… 
2012
2012
Cancer Therapy : Preclinical RAF 265 Inhibits the Growth of Advanced Human Melanoma Tumors
Purpose: The purpose of this preclinical study was to determine the effectiveness of RAF265, a multikinase inhibitor, for… 
2012
2012
Preclinical Development CEP-32496 : A Novel Orally Active BRAFV 600 E Inhibitor with Selective Cellular and In Vivo Antitumor Activity
Mutations in the BRAF gene have been identified in approximately 7% of cancers, including 60% to 70% of melanomas, 29% to 83% of… 
2011
2011
P5-06-08: Mesenchymal Stem Cells and Carcinoma-Associated Fibroblasts Sensitize Breast Cancer Cells in 3D Cultures to Kinase Inhibitors.
Background: Bone-derived mesenchymal stem cells (MSCs) are attracted to cancer lesions and may differentiate to CAFs. By… 
2010
2010
Blockade of Raf/MEK/ERK pathway by Raf265 inhibits tumor growth via in colorectal cancer
Poster Session 21 - Anticancer Drugs Targeting Cell Cycle and Proliferation: abstract no. 2508 
2010
2010
Inhibition of tumour growth by Raf265 via blockade of Raf/MEK/ERK pathway in colorectal cancer
Inhibition of tumour growth by Raf265 via blockade of Raf/MEK/ERK pathway in colorectal cancer AKM Chow, ACY Chu, RTPoon, BCY… 
2009
2009
Pharmacodynamics of 2- ethan-1-ol (GDC-0879), a Potent and Selective B-Raf Kinase Inhibitor: Understanding Relationships between Systemic Concentrations, Phosphorylated Mitogen-Activated Protein…
The Raf/mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase signaling pathway is involved in… 
2008
2008
[18F]Fluoroethylated VEGFR-2 tyrosine kinase inhibitors
2007
2007
VEGFR-2 / FGFR-1 Antagonist Treatment with Brivanib Alaninate , a Small-Molecule Discovery and Validation of Biomarkers that Respond to Updated
The process of neovascularization from preexisting blood vessels, referred to as angiogenesis, plays a critical role in both… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)